(Circulation. 1996;94:607-609.)
© 1996 American Heart Association, Inc.
Articles |
the Departments of Pharmacology and Pediatrics, College of Physicians and Surgeons, New York, NY.
Correspondence to Michael R. Rosen, MD, the Department of Pharmacology, College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032.
Key Words: Editorials arrhythmia antiarrhythmia agents
| Introduction |
|---|
The study by Roy et al1 is also a reminder that our knowledge concerning acquired long-QT syndrome is advancing with impressive rapidity in ways that impact directly on our understanding of pathophysiology and patient care. Families of drugs including but not limited to antiarrhythmics that prolong repolarization by blocking K+ channels or increasing inward Na+ currents,8 macrolide antibiotics, and pyrrole antimycotics3 4 5 6 7 all have the potential to prolong the QT interval and induce arrhythmias and/or death. With respect to the mechanism whereby nonsedating antihistamines prolong the QT interval, the focus of investigation has been the delayed rectifier current, IK. A major breakthrough here came in the report by Woosley et al4 demonstrating terfenadine block of IK in feline ventricle. Subsequently, terfenadine has been reported to block the transient outward current (Ito1) as well as the ultrarapid (IKur), rapid (IKr), and slow (IKs) components of
This article has been cited by other articles:
![]() |
W Haverkamp, G Breithardt, A.J Camm, M.J Janse, M.R Rosen, C Antzelevitch, D Escande, M Franz, M Malik, A Moss, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology Eur. Heart J., August 1, 2000; 21(15): 1216 - 1231. [PDF] |
||||
![]() |
W. Haverkamp, G. Breithardt, A.J. Camm, M. J Janse, M. R Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology Cardiovasc Res, August 1, 2000; 47(2): 219 - 233. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |